nevirapine has been researched along with Neutropenia in 7 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, C | 1 |
| Forster, JE | 1 |
| Levin, MJ | 1 |
| Davies, J | 1 |
| Pappas, J | 1 |
| Kinzie, K | 1 |
| Barr, E | 1 |
| Paul, S | 1 |
| McFarland, EJ | 1 |
| Weinberg, A | 1 |
| Kumwenda, NI | 1 |
| Hoover, DR | 1 |
| Mofenson, LM | 1 |
| Thigpen, MC | 1 |
| Kafulafula, G | 1 |
| Li, Q | 1 |
| Mipando, L | 1 |
| Nkanaunena, K | 1 |
| Mebrahtu, T | 1 |
| Bulterys, M | 1 |
| Fowler, MG | 2 |
| Taha, TE | 1 |
| Bae, WH | 1 |
| Wester, C | 2 |
| Smeaton, LM | 1 |
| Shapiro, RL | 2 |
| Lockman, S | 2 |
| Onyait, K | 1 |
| Thior, I | 2 |
| Essex, M | 2 |
| Mugyenyi, P | 3 |
| Walker, AS | 2 |
| Hakim, J | 3 |
| Munderi, P | 2 |
| Gibb, DM | 2 |
| Kityo, C | 2 |
| Reid, A | 2 |
| Grosskurth, H | 3 |
| Darbyshire, JH | 3 |
| Ssali, F | 2 |
| Bray, D | 2 |
| Katabira, E | 3 |
| Babiker, AG | 1 |
| Gilks, CF | 1 |
| Kabuye, G | 1 |
| Nsibambi, D | 2 |
| Kasirye, R | 1 |
| Zalwango, E | 1 |
| Nakazibwe, M | 1 |
| Kikaire, B | 1 |
| Nassuna, G | 1 |
| Massa, R | 1 |
| Fadhiru, K | 2 |
| Namyalo, M | 1 |
| Zalwango, A | 1 |
| Generous, L | 1 |
| Khauka, P | 2 |
| Rutikarayo, N | 1 |
| Nakahima, W | 1 |
| Mugisha, A | 1 |
| Todd, J | 1 |
| Levin, J | 1 |
| Muyingo, S | 1 |
| Ruberantwari, A | 1 |
| Kaleebu, P | 2 |
| Yirrell, D | 2 |
| Ndembi, N | 2 |
| Lyagoba, F | 2 |
| Hughes, P | 1 |
| Aber, M | 1 |
| Lara, AM | 2 |
| Foster, S | 2 |
| Amurwon, J | 2 |
| Wakholi, BN | 2 |
| Whitworth, J | 1 |
| Wangati, K | 1 |
| Amuron, B | 1 |
| Kajungu, D | 1 |
| Nakiyingi, J | 1 |
| Omony, W | 1 |
| Tumukunde, D | 1 |
| Otim, T | 1 |
| Kabanda, J | 1 |
| Musana, H | 1 |
| Akao, J | 1 |
| Kyomugisha, H | 1 |
| Byamukama, A | 1 |
| Sabiiti, J | 1 |
| Komugyena, J | 1 |
| Wavamunno, P | 1 |
| Mukiibi, S | 1 |
| Drasiku, A | 1 |
| Byaruhanga, R | 1 |
| Labeja, O | 1 |
| Katundu, P | 2 |
| Tugume, S | 2 |
| Awio, P | 1 |
| Namazzi, A | 1 |
| Bakeinyaga, GT | 1 |
| Katabira, H | 1 |
| Abaine, D | 1 |
| Tukamushaba, J | 1 |
| Anywar, W | 1 |
| Ojiambo, W | 1 |
| Angweng, E | 1 |
| Murungi, S | 2 |
| Haguma, W | 1 |
| Atwiine, S | 1 |
| Kigozi, J | 3 |
| Namale, L | 1 |
| Mukose, A | 1 |
| Mulindwa, G | 1 |
| Atwiine, D | 1 |
| Muhwezi, A | 1 |
| Nimwesiga, E | 1 |
| Barungi, G | 1 |
| Takubwa, J | 1 |
| Mwebesa, D | 1 |
| Kagina, G | 1 |
| Mulindwa, M | 1 |
| Ahimbisibwe, F | 1 |
| Mwesigwa, P | 1 |
| Akuma, S | 1 |
| Zawedde, C | 1 |
| Nyiraguhirwa, D | 1 |
| Tumusiime, C | 1 |
| Bagaya, L | 1 |
| Namara, W | 1 |
| Karungi, J | 1 |
| Kankunda, R | 1 |
| Enzama, R | 1 |
| Latif, A | 2 |
| Robertson, V | 2 |
| Chidziva, E | 1 |
| Bulaya-Tembo, R | 1 |
| Musoro, G | 1 |
| Taziwa, F | 1 |
| Chimbetete, C | 1 |
| Chakonza, L | 1 |
| Mawora, A | 1 |
| Muvirimi, C | 1 |
| Tinago, G | 1 |
| Svovanapasis, P | 1 |
| Simango, M | 1 |
| Chirema, O | 1 |
| Machingura, J | 1 |
| Mutsai, S | 1 |
| Phiri, M | 1 |
| Bafana, T | 1 |
| Chirara, M | 2 |
| Muchabaiwa, L | 2 |
| Muzambi, M | 2 |
| Mutowo, J | 1 |
| Chivhunga, T | 1 |
| Chigwedere, E | 1 |
| Pascoe, M | 1 |
| Warambwa, C | 1 |
| Zengeza, E | 1 |
| Mapinge, F | 1 |
| Makota, S | 1 |
| Jamu, A | 1 |
| Ngorima, N | 1 |
| Chirairo, H | 1 |
| Chitsungo, S | 1 |
| Chimanzi, J | 1 |
| Maweni, C | 1 |
| Warara, R | 1 |
| Matongo, M | 1 |
| Mudzingwa, S | 1 |
| Jangano, M | 1 |
| Moyo, K | 1 |
| Vere, L | 1 |
| Mdege, N | 1 |
| Machingura, I | 1 |
| Ronald, A | 1 |
| Kambungu, A | 1 |
| Lutwama, F | 1 |
| Mambule, I | 1 |
| Nanfuka, A | 1 |
| Walusimbi, J | 1 |
| Nabankema, E | 1 |
| Nalumenya, R | 1 |
| Namuli, T | 1 |
| Kulume, R | 1 |
| Namata, I | 1 |
| Nyachwo, L | 1 |
| Florence, A | 1 |
| Kusiima, A | 1 |
| Lubwama, E | 1 |
| Nairuba, R | 1 |
| Oketta, F | 1 |
| Buluma, E | 1 |
| Waita, R | 1 |
| Ojiambo, H | 1 |
| Sadik, F | 1 |
| Wanyama, J | 1 |
| Nabongo, P | 1 |
| Oyugi, J | 1 |
| Sematala, F | 1 |
| Muganzi, A | 1 |
| Twijukye, C | 1 |
| Byakwaga, H | 1 |
| Ochai, R | 1 |
| Muhweezi, D | 1 |
| Coutinho, A | 1 |
| Etukoit, B | 1 |
| Gilks, C | 2 |
| Boocock, K | 1 |
| Puddephatt, C | 1 |
| Grundy, C | 1 |
| Bohannon, J | 1 |
| Winogron, D | 1 |
| Burke, A | 1 |
| Babiker, A | 2 |
| Wilkes, H | 1 |
| Rauchenberger, M | 1 |
| Sheehan, S | 1 |
| Spencer-Drake, C | 1 |
| Taylor, K | 1 |
| Spyer, M | 1 |
| Ferrier, A | 1 |
| Naidoo, B | 1 |
| Dunn, D | 2 |
| Goodall, R | 2 |
| Peto, L | 1 |
| Nanfuka, R | 1 |
| Mufuka-Kapuya, C | 1 |
| Pillay, D | 1 |
| McCormick, A | 1 |
| Weller, I | 1 |
| Bahendeka, S | 1 |
| Bassett, M | 1 |
| Wapakhabulo, AC | 1 |
| Gazzard, B | 1 |
| Mapuchere, C | 1 |
| Mugurungi, O | 1 |
| Burke, C | 1 |
| Jones, S | 1 |
| Newland, C | 1 |
| Pearce, G | 1 |
| Rahim, S | 1 |
| Rooney, J | 1 |
| Smith, M | 1 |
| Snowden, W | 2 |
| Steens, JM | 1 |
| Breckenridge, A | 1 |
| McLaren, A | 1 |
| Hill, C | 1 |
| Matenga, J | 1 |
| Pozniak, A | 1 |
| Serwadda, D | 1 |
| Peto, T | 1 |
| Palfreeman, A | 1 |
| Borok, M | 1 |
| Chasela, CS | 1 |
| Hudgens, MG | 1 |
| Jamieson, DJ | 1 |
| Kayira, D | 1 |
| Hosseinipour, MC | 1 |
| Kourtis, AP | 1 |
| Martinson, F | 1 |
| Tegha, G | 1 |
| Knight, RJ | 1 |
| Ahmed, YI | 1 |
| Kamwendo, DD | 1 |
| Hoffman, IF | 1 |
| Ellington, SR | 1 |
| Kacheche, Z | 1 |
| Soko, A | 1 |
| Wiener, JB | 1 |
| Fiscus, SA | 1 |
| Kazembe, P | 1 |
| Mofolo, IA | 1 |
| Chigwenembe, M | 1 |
| Sichali, DS | 1 |
| van der Horst, CM | 1 |
| Hughes, MD | 1 |
| Ogwu, A | 1 |
| Kitch, D | 1 |
| Moffat, C | 1 |
| Makhema, J | 1 |
| Moyo, S | 1 |
| McIntosh, K | 1 |
| van Widenfelt, E | 1 |
| Leidner, J | 1 |
| Powis, K | 1 |
| Asmelash, A | 1 |
| Tumbare, E | 1 |
| Zwerski, S | 1 |
| Sharma, U | 1 |
| Handelsman, E | 1 |
| Mburu, K | 1 |
| Jayeoba, O | 1 |
| Moko, E | 1 |
| Souda, S | 1 |
| Lubega, E | 1 |
| Akhtar, M | 1 |
| Tuomola, R | 1 |
| Martinez-Tristani, M | 1 |
| Mazhani, L | 1 |
| Aizire, J | 1 |
| Wang, J | 1 |
| Shetty, AK | 1 |
| Stranix-Chibanda, L | 1 |
| Kamateeka, M | 1 |
| Brown, ER | 1 |
| Bolton, SG | 1 |
| Musoke, PM | 1 |
| Coovadia, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission[NCT00115648] | Phase 3 | 3,300 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants[NCT01388452] | 300 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health[NCT00164736] | Phase 3 | 2,369 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975] | 200 participants (Anticipated) | Observational | 2024-01-08 | Not yet recruiting | |||
| Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana[NCT00270296] | Phase 2 | 730 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of infants with HIV-positive status (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months
| Intervention | Infants (Number) |
|---|---|
| TZV Arm | 6 |
| Kaletra Arm | 1 |
| NVP Arm | 1 |
Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| TZV Arm | 274 |
| Kaletra Arm | 256 |
| NVP Arm | 160 |
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
6 trials available for nevirapine and Neutropenia
| Article | Year |
|---|---|
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2008 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.
Topics: Adult; Anemia; Anti-HIV Agents; Blotting, Western; Breast Feeding; Drug Administration Schedule; Dru | 2012 |
1 other study available for nevirapine and Neutropenia
| Article | Year |
|---|---|
Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review.
Topics: Anemia; Anti-HIV Agents; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Infecti | 2015 |